| A Novel Intervention for Patients With Cancer (NCT05643027) | Dana-Farber Cancer Institute | 2023-03-01 |
| Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials (NCT06888089) | Dana-Farber Cancer Institute | 2023-01-30 |
| Biology of Young Lung Cancer Study: The YOUNG LUNG Study (NCT05265429) | Dana-Farber Cancer Institute | 2023-01-01 |
| Investigating Hereditary Risk In Thoracic Cancers (INHERIT) (NCT05587439) | Dana-Farber Cancer Institute | 2023-01-01 |
| Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation (NCT05600101) | Dana-Farber Cancer Institute | 2022-12-06 |
| The SPOT-HPV Study (NCT05524025) | Dana-Farber Cancer Institute | 2022-11-30 |
| Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC) (NCT05629065) | Dana-Farber Cancer Institute | 2022-11-28 |
| Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA) (NCT05358951) | Dana-Farber Cancer Institute | 2022-11-19 |
| Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study (NCT05327452) | Dana-Farber Cancer Institute | 2022-10-31 |
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 (NCT05482074) | Dana-Farber Cancer Institute | 2022-10-04 |
| Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) (NCT05528263) | Dana-Farber Cancer Institute | 2022-09-08 |
| SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care (NCT04368130) | Dana-Farber Cancer Institute | 2022-09-01 |
| Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial (NCT05356117) | Dana-Farber Cancer Institute | 2022-09-01 |
| Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy (NCT05327465) | Dana-Farber Cancer Institute | 2022-08-11 |
| GROW (Glioma Specialists Reaching Out With Support) Support (NCT05233215) | Dana-Farber Cancer Institute | 2022-07-01 |
| Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation (NCT05335434) | Dana-Farber Cancer Institute | 2022-06-10 |
| Early Interventional Treatment for Cancer Pain (NCT05366413) | Dana-Farber Cancer Institute | 2022-06-02 |
| Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial (NCT05236062) | Dana-Farber Cancer Institute | 2022-04-14 |
| Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (NCT04997096) | Dana-Farber Cancer Institute | 2022-04-02 |
| Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (NCT03361852) | Dana-Farber Cancer Institute | 2022-03-14 |
| ASP8374 + Cemiplimab in Recurrent Glioma (NCT04826393) | Dana-Farber Cancer Institute | 2022-03-09 |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (NCT05168930) | Dana-Farber Cancer Institute | 2022-02-18 |
| UPLYFT For Lymphoma Survivors (NCT05080166) | Dana-Farber Cancer Institute | 2022-02-08 |
| RCT of CBD for Anxiety in Advanced Breast Cancer (NCT04482244) | Dana-Farber Cancer Institute | 2022-01-19 |
| Resilience and Equity in Aging, Cancer, and Health (REACH) (NCT04674267) | Dana-Farber Cancer Institute | 2022-01-18 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (NCT04930783) | Dana-Farber Cancer Institute | 2022-01-03 |
| Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial (NCT04883671) | Dana-Farber Cancer Institute | 2021-12-27 |
| Abemaciclib + Pembrolizumab In Glioblastoma (NCT04118036) | Dana-Farber Cancer Institute | 2021-12-01 |
| The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) (NCT05121558) | Dana-Farber Cancer Institute | 2021-10-29 |
| Scalp Cooling in MBC (NCT04986579) | Dana-Farber Cancer Institute | 2021-10-07 |
| Venetoclax Plus Inotuzumab for B-ALL (NCT05016947) | Dana-Farber Cancer Institute | 2021-09-24 |
| Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity (NCT04717050) | Dana-Farber Cancer Institute | 2021-09-23 |
| Copanlisib Plus Venetoclax in R/R DLBCL (NCT04572763) | Dana-Farber Cancer Institute | 2021-09-08 |
| Abemaciclib With or Without Atezolizumab for mCRPC (NCT04751929) | Dana-Farber Cancer Institute | 2021-08-20 |
| TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance) (NCT04936243) | Dana-Farber Cancer Institute | 2021-08-01 |
| Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia (NCT04839614) | Dana-Farber Cancer Institute | 2021-08-01 |
| Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML (NCT04908852) | Dana-Farber Cancer Institute | 2021-07-26 |
| Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy (NCT04724499) | Dana-Farber Cancer Institute | 2021-07-14 |
| My Mindful Moments: A Mindfulness Meditation and Digital Art Activity (NCT04557033) | Dana-Farber Cancer Institute | 2021-07-01 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets (NCT04899921) | Dana-Farber Cancer Institute | 2021-06-30 |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC (NCT04846478) | Dana-Farber Cancer Institute | 2021-06-28 |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH (NCT04893109) | Dana-Farber Cancer Institute | 2021-06-16 |
| Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens (NCT04968834) | Dana-Farber Cancer Institute | 2021-06-11 |
| Dilute Bleach Compresses for Radiation Dermatitis (NCT04851522) | Dana-Farber Cancer Institute | 2021-06-09 |
| Refining Local-Regional Therapy for IBC (NCT04636710) | Dana-Farber Cancer Institute | 2021-06-02 |
| Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer (NCT04789486) | Dana-Farber Cancer Institute | 2021-05-27 |
| Survivor-Sleep Health Information Program (NCT04863157) | Dana-Farber Cancer Institute | 2021-05-24 |
| The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) (NCT04917796) | Dana-Farber Cancer Institute | 2021-05-21 |
| Sacituzumab Govitecan Plus EV in Metastatic UC (NCT04724018) | Dana-Farber Cancer Institute | 2021-05-20 |
| Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement (NCT04879927) | Dana-Farber Cancer Institute | 2021-05-17 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma (NCT04850846) | Dana-Farber Cancer Institute | 2021-04-27 |
| Sargramostim (GM-CSF) + PD-1 (NCT04703426) | Dana-Farber Cancer Institute | 2021-04-16 |
| Safe Accelerated Venetoclax Escalation in CLL (NCT04843904) | Dana-Farber Cancer Institute | 2021-04-14 |
| Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes (NCT04323774) | Dana-Farber Cancer Institute | 2021-03-01 |
| AWARENESS Trial (AWARENESS) of Storytelling Through Music in Healthcare Workers (NCT04775524) | Dana-Farber Cancer Institute | 2021-03-01 |
| Digitally Enhanced Smoking Cessation for High Risk Smokers (NCT04691297) | Dana-Farber Cancer Institute | 2021-02-01 |
| Step Into Support for Endurance and Strength (SISTERS) (NCT04354454) | Dana-Farber Cancer Institute | 2021-01-29 |
| Feasibility of Fasting & Exercise in Pts With HR+ MBC (NCT04708860) | Dana-Farber Cancer Institute | 2021-01-15 |
| IS-free Treg HaploHCT (NCT04678401) | Dana-Farber Cancer Institute | 2021-01-12 |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (NCT04569747) | Dana-Farber Cancer Institute | 2021-01-11 |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (NCT04620187) | Dana-Farber Cancer Institute | 2020-12-24 |
| Cabozantinib With Topotecan-Cyclophosphamide (NCT04661852) | Dana-Farber Cancer Institute | 2020-12-23 |
| Advance Care Planning: Communicating With Outpatients for Vital Informed Decision (NCT04660422) | Dana-Farber Cancer Institute | 2020-12-15 |
| Axi-cel in CNS Lymphoma (NCT04608487) | Dana-Farber Cancer Institute | 2020-12-04 |
| Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers (NCT04330716) | Dana-Farber Cancer Institute | 2020-12-01 |
| RESIST-ADT (Androgen Deprivation Therapy) (NCT04485767) | Dana-Farber Cancer Institute | 2020-12-01 |
| Olaparib With Ceralasertib in Recurrent Osteosarcoma (NCT04417062) | Dana-Farber Cancer Institute | 2020-11-24 |
| NeoVax With Nivolumab in Patients With Ovarian Cancer (NCT04024878) | Dana-Farber Cancer Institute | 2020-11-20 |
| Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (NCT03929029) | Dana-Farber Cancer Institute | 2020-11-11 |
| Effect of Perampanel on Peritumoral Hyperexcitability in HGG (NCT04497142) | Dana-Farber Cancer Institute | 2020-11-05 |
| Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy (NCT04479514) | Dana-Farber Cancer Institute | 2020-10-01 |
| YES Study - Newly Diagnosed/Metastatic Intervention (NCT04379414) | Dana-Farber Cancer Institute | 2020-09-16 |
| Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress (NCT04541654) | Dana-Farber Cancer Institute | 2020-09-15 |
| Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers (NCT04416568) | Dana-Farber Cancer Institute | 2020-08-14 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG (NCT04341311) | Dana-Farber Cancer Institute | 2020-08-10 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL (NCT04421560) | Dana-Farber Cancer Institute | 2020-08-01 |
| VB-111 in Surgically Accessible Recurrent/Progressive GBM (NCT04406272) | Dana-Farber Cancer Institute | 2020-08-01 |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (NCT04468061) | Dana-Farber Cancer Institute | 2020-07-20 |
| CIML NK Cell in Head & Neck Cancer (NCT04290546) | Dana-Farber Cancer Institute | 2020-07-20 |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy (NCT04081259) | Dana-Farber Cancer Institute | 2020-07-15 |
| MARGetuximab Or Trastuzumab (MARGOT) (NCT04425018) | Dana-Farber Cancer Institute | 2020-07-13 |
| Ibrutinib + Venetoclax in Untreated WM (NCT04273139) | Dana-Farber Cancer Institute | 2020-07-09 |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) (NCT04434040) | Dana-Farber Cancer Institute | 2020-07-02 |
| Tucatinib + Abemaciclib + Herceptin for HER2+ MBC (NCT03846583) | Dana-Farber Cancer Institute | 2020-06-28 |
| Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT (NCT03777982) | Dana-Farber Cancer Institute | 2020-04-20 |
| Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (NCT03609177) | Dana-Farber Cancer Institute | 2020-04-15 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845) | Dana-Farber Cancer Institute | 2020-02-03 |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies (NCT03717480) | Dana-Farber Cancer Institute | 2020-01-21 |
| Serial MRI Scans During Radiation Therapy (NCT04188535) | Dana-Farber Cancer Institute | 2020-01-15 |
| Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (NCT04071756) | Dana-Farber Cancer Institute | 2019-12-30 |
| OPTimizing Treatment Focused Genetic Testing IN Cancer (NCT04066361) | Dana-Farber Cancer Institute | 2019-12-19 |
| Videos for Advance Care Planning in Young Adults (NCT04149704) | Dana-Farber Cancer Institute | 2019-12-13 |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma (NCT04045470) | Dana-Farber Cancer Institute | 2019-12-11 |
| Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression (NCT04040725) | Dana-Farber Cancer Institute | 2019-11-27 |
| Smart Phone App Intervention In Young Adults With Cancer (NCT04119869) | Dana-Farber Cancer Institute | 2019-11-11 |
| Stereotactic Magnetic Resonance Guided Radiation Therapy (NCT04115254) | Dana-Farber Cancer Institute | 2019-10-22 |
| Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (NCT03936465) | Dana-Farber Cancer Institute | 2019-09-27 |
| The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids (NCT03993210) | Dana-Farber Cancer Institute | 2019-09-18 |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (NCT04007588) | Dana-Farber Cancer Institute | 2019-09-06 |
| Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study (NCT03824860) | Dana-Farber Cancer Institute | 2019-08-06 |